{"title":"Tivozanib monotherapy outperforms combination therapy in post-ICI RCC","authors":"Maria Chiara Masone","doi":"10.1038/s41585-024-00971-y","DOIUrl":null,"url":null,"abstract":"<p>The multicentre, randomized, phase III trial TiNivo-2 was conducted to assess the efficacy of the vascular endothelial growth factor receptor inhibitor tivozanib alone versus in combination with the immune checkpoint inhibitor (ICI) nivolumab in patients with advanced renal cell carcinoma (RCC) who had progressed during or after 1–2 previous lines of therapy including one ICI. Progression-free survival (PFS) was higher in patients in the monotherapy group (7.4 months) than in patients receiving combination therapy (5.7 months; HR 1.10, 95% CI 0.84–1.43; <i>P</i> = 0.49). These results show that re-challenging patients with advanced RCC with ICI therapy is not advisable and suggest tivozanib monotherapy as a viable treatment option in the post-ICI setting.</p>","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":"2 1","pages":""},"PeriodicalIF":12.1000,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41585-024-00971-y","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The multicentre, randomized, phase III trial TiNivo-2 was conducted to assess the efficacy of the vascular endothelial growth factor receptor inhibitor tivozanib alone versus in combination with the immune checkpoint inhibitor (ICI) nivolumab in patients with advanced renal cell carcinoma (RCC) who had progressed during or after 1–2 previous lines of therapy including one ICI. Progression-free survival (PFS) was higher in patients in the monotherapy group (7.4 months) than in patients receiving combination therapy (5.7 months; HR 1.10, 95% CI 0.84–1.43; P = 0.49). These results show that re-challenging patients with advanced RCC with ICI therapy is not advisable and suggest tivozanib monotherapy as a viable treatment option in the post-ICI setting.
期刊介绍：
Nature Reviews Urology is part of the Nature Reviews portfolio of journals.Nature Reviews' basic, translational and clinical content is written by internationally renowned basic and clinical academics and researchers. This journal targeted readers in the biological and medical sciences, from the postgraduate level upwards, aiming to be accessible to professionals in any biological or medical discipline.
The journal features authoritative In-depth Reviews providing up-to-date information on topics within a field's history and development. Perspectives, News & Views articles, and the Research Highlights section offer topical discussions and opinions, filtering primary research from various medical journals.
Covering a wide range of subjects, including andrology, urologic oncology, and imaging, Nature Reviews provides valuable insights for practitioners, researchers, and academics within urology and related fields.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
